TW202302862A - 染色體交互作用標記物 - Google Patents
染色體交互作用標記物 Download PDFInfo
- Publication number
- TW202302862A TW202302862A TW111107496A TW111107496A TW202302862A TW 202302862 A TW202302862 A TW 202302862A TW 111107496 A TW111107496 A TW 111107496A TW 111107496 A TW111107496 A TW 111107496A TW 202302862 A TW202302862 A TW 202302862A
- Authority
- TW
- Taiwan
- Prior art keywords
- cdata
- cancer
- dna
- homo sapiens
- immunotherapy
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title claims abstract description 111
- 210000000349 chromosome Anatomy 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 130
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 87
- 238000009169 immunotherapy Methods 0.000 claims abstract description 80
- 201000011510 cancer Diseases 0.000 claims abstract description 60
- 108020004414 DNA Proteins 0.000 claims description 249
- 239000000523 sample Substances 0.000 claims description 124
- 230000002759 chromosomal effect Effects 0.000 claims description 113
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 52
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 47
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 47
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 36
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 238000002560 therapeutic procedure Methods 0.000 claims description 34
- 238000001514 detection method Methods 0.000 claims description 32
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 28
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 22
- 230000001973 epigenetic effect Effects 0.000 claims description 18
- 238000002648 combination therapy Methods 0.000 claims description 17
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 16
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 16
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 210000000987 immune system Anatomy 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 14
- 238000003753 real-time PCR Methods 0.000 claims description 14
- 238000002619 cancer immunotherapy Methods 0.000 claims description 12
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 11
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 11
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 7
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 210000004443 dendritic cell Anatomy 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 6
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 5
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000010505 Nose Neoplasms Diseases 0.000 claims description 4
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000037830 nasal cancer Diseases 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 201000001219 parotid gland cancer Diseases 0.000 claims description 4
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000032383 Soft tissue cancer Diseases 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000005304 joining Methods 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 238000011895 specific detection Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 239000012272 PD-L2 inhibitor Substances 0.000 claims description 2
- 230000005880 cancer cell killing Effects 0.000 claims description 2
- 229940121654 pd-l2 inhibitor Drugs 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 3
- 230000008569 process Effects 0.000 abstract description 7
- 241000282414 Homo sapiens Species 0.000 description 207
- 208000037821 progressive disease Diseases 0.000 description 138
- 229960002621 pembrolizumab Drugs 0.000 description 70
- 230000004044 response Effects 0.000 description 68
- 239000013615 primer Substances 0.000 description 51
- 239000002987 primer (paints) Substances 0.000 description 51
- 239000003550 marker Substances 0.000 description 50
- 229960003852 atezolizumab Drugs 0.000 description 42
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 34
- 230000036961 partial effect Effects 0.000 description 31
- 238000003752 polymerase chain reaction Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 27
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 25
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 23
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 23
- 210000005155 neural progenitor cell Anatomy 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 206010061289 metastatic neoplasm Diseases 0.000 description 18
- 239000000090 biomarker Substances 0.000 description 17
- 229950009791 durvalumab Drugs 0.000 description 17
- 210000004072 lung Anatomy 0.000 description 17
- 230000001394 metastastic effect Effects 0.000 description 17
- 229950002916 avelumab Drugs 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000012549 training Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000000513 principal component analysis Methods 0.000 description 12
- 238000003491 array Methods 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000004043 responsiveness Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 206010050017 Lung cancer metastatic Diseases 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000002493 microarray Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000008482 dysregulation Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 229960005386 ipilimumab Drugs 0.000 description 6
- 229960003301 nivolumab Drugs 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000007857 nested PCR Methods 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000003066 decision tree Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 4
- 210000003681 parotid gland Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 101001062093 Homo sapiens RNA-binding protein 15 Proteins 0.000 description 3
- 229940127145 L19-IL2 immunocytokine Drugs 0.000 description 3
- 229940127147 L19-TNF immunocytokine Drugs 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 102100029244 RNA-binding protein 15 Human genes 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 230000007023 DNA restriction-modification system Effects 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 208000007666 Klatskin Tumor Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 208000037844 advanced solid tumor Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000012772 sequence design Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 229940032072 GVAX vaccine Drugs 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 description 1
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 description 1
- 229940123776 Immuno-oncology therapy Drugs 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000033793 Neuroendocrine tumor of stomach Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033610 Pancreatic carcinoma metastatic Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000638935 Senecio crassissimus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 101710159262 Transcription termination factor 1 Proteins 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 101150092805 actc1 gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- MHHMNDJIDRZZNT-UHFFFAOYSA-N atto 680 Chemical compound OC(=O)CCCN1C(C)(C)C=C(CS([O-])(=O)=O)C2=C1C=C1OC3=CC4=[N+](CC)CCCC4=CC3=NC1=C2 MHHMNDJIDRZZNT-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 230000010319 checkpoint response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000035612 epigenetic expression Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000018060 hilar cholangiocarcinoma Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229940127130 immunocytokine Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- -1 ipilimumab Chemical compound 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 208000037993 perihilar cancer Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229940034049 polysaccharide-k Drugs 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 208000012049 salivary gland mucoepidermoid carcinoma Diseases 0.000 description 1
- 229940018073 sasanlimab Drugs 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 201000010986 transverse colon cancer Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156659P | 2021-03-04 | 2021-03-04 | |
| US63/156,659 | 2021-03-04 | ||
| US202163282284P | 2021-11-23 | 2021-11-23 | |
| US63/282,284 | 2021-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202302862A true TW202302862A (zh) | 2023-01-16 |
Family
ID=80735500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111107496A TW202302862A (zh) | 2021-03-04 | 2022-03-02 | 染色體交互作用標記物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240229135A9 (enExample) |
| EP (1) | EP4301874B1 (enExample) |
| JP (1) | JP2024511292A (enExample) |
| KR (1) | KR20240006020A (enExample) |
| AU (1) | AU2022230780B2 (enExample) |
| BR (1) | BR112023017802A2 (enExample) |
| CA (1) | CA3209544A1 (enExample) |
| ES (1) | ES3029416T3 (enExample) |
| GB (1) | GB2618727B (enExample) |
| HU (1) | HUE071359T2 (enExample) |
| IL (1) | IL304883A (enExample) |
| PL (1) | PL4301874T3 (enExample) |
| TW (1) | TW202302862A (enExample) |
| WO (1) | WO2022185062A1 (enExample) |
| ZA (1) | ZA202309162B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202412610D0 (en) * | 2024-08-28 | 2024-10-09 | Oxford BioDynamics PLC | Screening method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511930B (zh) * | 2017-11-03 | 2024-11-22 | 牛津生物动力有限责任公司 | 通过染色体相互作用遗传调节免疫响应 |
| WO2020198676A1 (en) * | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| GB2626699B (en) * | 2019-05-08 | 2024-11-20 | Oxford BioDynamics PLC | Chromosome Conformation Markers of Prostate Cancer and Lymphoma |
| WO2021228888A1 (en) * | 2020-05-12 | 2021-11-18 | Asylia Diagnostics | Biomarkers for hyperprogressive disease and therapy response after immunotherapy |
-
2022
- 2022-03-02 TW TW111107496A patent/TW202302862A/zh unknown
- 2022-03-03 BR BR112023017802A patent/BR112023017802A2/pt unknown
- 2022-03-03 ES ES22709783T patent/ES3029416T3/es active Active
- 2022-03-03 IL IL304883A patent/IL304883A/en unknown
- 2022-03-03 PL PL22709783.9T patent/PL4301874T3/pl unknown
- 2022-03-03 AU AU2022230780A patent/AU2022230780B2/en active Active
- 2022-03-03 JP JP2023553436A patent/JP2024511292A/ja active Pending
- 2022-03-03 KR KR1020237033851A patent/KR20240006020A/ko active Pending
- 2022-03-03 EP EP22709783.9A patent/EP4301874B1/en active Active
- 2022-03-03 US US18/547,579 patent/US20240229135A9/en active Pending
- 2022-03-03 HU HUE22709783A patent/HUE071359T2/hu unknown
- 2022-03-03 WO PCT/GB2022/050561 patent/WO2022185062A1/en not_active Ceased
- 2022-03-03 CA CA3209544A patent/CA3209544A1/en active Pending
- 2022-03-03 GB GB2313067.7A patent/GB2618727B/en active Active
-
2023
- 2023-09-28 ZA ZA2023/09162A patent/ZA202309162B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024511292A (ja) | 2024-03-13 |
| US20240229135A9 (en) | 2024-07-11 |
| BR112023017802A2 (pt) | 2023-12-12 |
| AU2022230780A1 (en) | 2023-10-12 |
| EP4301874C0 (en) | 2025-04-23 |
| HUE071359T2 (hu) | 2025-08-28 |
| ES3029416T3 (en) | 2025-06-24 |
| EP4301874B1 (en) | 2025-04-23 |
| GB202313067D0 (en) | 2023-10-11 |
| WO2022185062A1 (en) | 2022-09-09 |
| AU2022230780B2 (en) | 2024-05-23 |
| ZA202309162B (en) | 2025-03-26 |
| GB2618727A (en) | 2023-11-15 |
| US20240132959A1 (en) | 2024-04-25 |
| PL4301874T3 (pl) | 2025-06-23 |
| GB2618727B (en) | 2024-07-17 |
| KR20240006020A (ko) | 2024-01-12 |
| CA3209544A1 (en) | 2022-09-09 |
| EP4301874A1 (en) | 2024-01-10 |
| IL304883A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7297015B2 (ja) | エピジェネティックな染色体相互作用 | |
| Julià et al. | An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis | |
| US11047011B2 (en) | Immunorepertoire normality assessment method and its use | |
| US11746378B2 (en) | Detection of chromosome interaction relevant to breast cancer | |
| JP7631400B2 (ja) | 遺伝子調節 | |
| KR20220060198A (ko) | 유전자 복제수 변이 정보를 이용하여 췌장암 환자의 생존 예후를 예측하는 방법 | |
| JP2025032205A (ja) | 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー | |
| TW202242135A (zh) | 分析方法 | |
| US20240229135A9 (en) | Chromosome Interaction Markers | |
| US11535893B2 (en) | Typing method | |
| Alfaro et al. | Molecular testing for targeted therapies and pharmacogenomics | |
| US20220333199A1 (en) | Diagnostic Chromosome Marker | |
| CN117795098A (zh) | 染色体相互作用标志物 | |
| HK40084342A (en) | Immunorepertoire normality assessment method and its use | |
| WO2025062136A1 (en) | Chromosome detection assay | |
| US20210027859A1 (en) | Method, Apparatus and System to Detect Indels and Tandem Duplications Using Single Cell DNA Sequencing | |
| HK40033107A (en) | Genetic regulation of immunoresponse by chromosome interactions | |
| HK40033107B (en) | Genetic regulation of immunoresponse by chromosome interactions |